Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Income towards Parent Company (2024 - 2025)

Historic Income towards Parent Company for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to -$20.4 million.

  • Prelude Therapeutics' Income towards Parent Company rose 4060.39% to -$20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$54.2 million, marking a year-over-year change of. This contributed to the annual value of -$139.7 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Prelude Therapeutics' Income towards Parent Company is -$20.4 million, which was up 4060.39% from -$33.8 million recorded in Q4 2024.
  • Prelude Therapeutics' 5-year Income towards Parent Company high stood at -$20.4 million for Q3 2025, and its period low was -$34.4 million during Q3 2024.